Medicare Enrolled
Dr. Neil Nimkar
Hematology & Oncology · Springfield, NJ
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Nimkar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nimkar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Nimkar
Dr. Neil Nimkar is a hematology & oncology specialist in Springfield, NJ, with 11 years of NPI registration. Based on federal Medicare data, Dr. Nimkar performed 1,350 Medicare services across 990 unique beneficiaries.
Between the years covered by Open Payments, Dr. Nimkar received a total of $4,467 from 50 pharmaceutical and/or device companies across 196 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Nimkar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 11 years in practice
▲ 1,350 Medicare services
$4,467 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,350
Medicare services
Bottom 42% in NJ for hematology & oncology
990
Unique beneficiaries
$115
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~123 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
396 | $149 | $488 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
210 | $99 | $343 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
198 | $72 | $247 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
197 | $146 | $733 |
| New patient office visit, complex (60-74 min) | 88 | $177 | $691 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
83 | $67 | $240 |
| Initial nursing facility care, moderate complexity Initial care provided to a patient in a nursing facility with moderate medical decision making, taking at least 35 minutes. |
57 | $115 | $432 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
39 | $1 | $9 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
34 | $13 | $72 |
| Nursing facility visit, low complexity A daily follow-up visit for an existing patient in a nursing facility involving straightforward medical decision making. The visit requires at least 15 minutes of time if time is used to determine the level of care. |
27 | $64 | $231 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
21 | $98 | $363 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$4,467
Total received (2021-2024)
Avg $1,117/year across 4 years
Top 42% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
50
Companies
196
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,015 (67.5%)
Other
Charitable contributions, space rental, and other categories
$1,338 (29.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$115 (2.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,159
2023
$995
2022
$730
2021
$583
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,110
PFIZER INC.
$188
Genentech USA, Inc.
$92
E.R. Squibb & Sons, L.L.C.
$66
Pharmacosmos Therapeutics Inc.
$58
ABBVIE INC.
$57
BeiGene USA, Inc.
$48
Celgene Corporation
$46
Merck Sharp & Dohme LLC
$44
GlaxoSmithKline, LLC.
$40
Astellas Pharma US Inc
$39
Janssen Biotech, Inc.
$38
Regeneron Healthcare Solutions, Inc.
$36
Daiichi Sankyo Inc.
$36
TAIHO ONCOLOGY, INC.
$36
Adaptive Biotechnologies Corporation
$22
Incyte Corporation
$22
Bayer Healthcare Pharmaceuticals Inc.
$21
Mirati Therapeutics, Inc.
$20
Eisai Inc.
$20
Tempus AI, Inc
$19
Rigel Pharmaceuticals, Inc.
$18
Deciphera Pharmaceuticals Inc.
$17
Azurity Pharmaceuticals, Inc.
$17
Exelixis Inc.
$17
ARRAY BIOPHARMA INC
$17
SERVIER PHARMACEUTICALS LLC
$14
Top 3 companies account for 64.4% of 2024 payments
All-time payments by company (2021-2024) ›
Novartis Pharmaceuticals Corporation
$1,322
PFIZER INC.
$289
NOVARTIS PHARMACEUTICALS CORPORATION
$278
Seagen Inc.
$195
Genentech USA, Inc.
$173
E.R. Squibb & Sons, L.L.C.
$166
Amgen Inc.
$153
Janssen Biotech, Inc.
$153
Merck Sharp & Dohme LLC
$98
Exelixis Inc.
$91
Celgene Corporation
$89
ARRAY BIOPHARMA INC
$80
Janssen Pharmaceuticals, Inc
$74
Astellas Pharma US Inc
$71
Daiichi Sankyo Inc.
$65
Mirati Therapeutics, Inc.
$64
BeiGene USA, Inc.
$63
Sirtex Medical Inc
$60
Kite Pharma, Inc.
$59
Pharmacosmos Therapeutics Inc.
$58
GlaxoSmithKline, LLC.
$58
Incyte Corporation
$58
ABBVIE INC.
$57
Regeneron Healthcare Solutions, Inc.
$54
Lilly USA, LLC
$48
Foundation Medicine, Inc.
$46
Adaptive Biotechnologies Corporation
$43
Rigel Pharmaceuticals, Inc.
$41
Bayer HealthCare Pharmaceuticals Inc.
$37
Merck Sharp & Dohme Corporation
$36
TAIHO ONCOLOGY, INC.
$36
Takeda Pharmaceuticals U.S.A., Inc.
$35
Eisai Inc.
$34
CTI BioPharma Corp.
$29
PharmaEssentia USA Corporation
$29
Bayer Healthcare Pharmaceuticals Inc.
$21
Tempus AI, Inc
$19
Deciphera Pharmaceuticals Inc.
$17
Azurity Pharmaceuticals, Inc.
$17
Karyopharm Therapeutics Inc.
$16
MorphoSys, US Inc.
$15
AbbVie Inc.
$15
Welch Allyn
$15
TerSera Therapeutics LLC
$14
ImmunoGen, Inc.
$14
SERVIER PHARMACEUTICALS LLC
$14
Pharmacyclics LLC, an AbbVie Company
$13
Baxter Healthcare
$13
Genmab U.S., Inc.
$13
EMD Serono, Inc.
$10
Top 3 companies account for 42.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Alecensa · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABOMETYX · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · ELAHERE · ELIQUIS · ELREXFIO · EPKINLY · ERLEADA · Elahere · Enhertu · Fabhalta · IBRANCE · IMBRUVICA · INLYTA · JAKAFI · JEMPERLI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · NINLARO · None · Nplate · Nubeqa · OPDIVO · OPDUALAG · PADCEV · PEMAZYRE · PLUVICTO · PROMACTA · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · Rezlidhia · SCEMBLIX · SIR-Spheres Microspheres · Stivarga · TALVEY · TECVAYLI · TRIPTODUR · TUKYSA · Tavalisse · Tecentriq · Tivdak · VENCLEXTA · VERZENIO · Venclexta · Vonjo · Vyloy · XALKORI · XARELTO · XPOVIO · XTANDI · XYNTHA · Xospata · Yescarta · ZEJULA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (68%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
602
Per 100K population
105.1
County median income
$100,117
Nearest hospital
OVERLOOK MEDICAL CENTER
2.0 mi
2.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Nimkar is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Nimkar experienced with office visit, established patient, complex (40-54 min)?
Based on Medicare claims data, Dr. Nimkar performed 396 office visit, established patient, complex (40-54 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nimkar receive payments from pharmaceutical companies?
Yes. Dr. Nimkar received a total of $4,467 from 50 companies across 196 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nimkar's costs compare to other hematology & oncology specialists in Springfield?
Dr. Nimkar's average Medicare payment per service is $115. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nimkar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Springfield
Browse hematology & oncology specialists in Springfield ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
NOVARTIS PHARMACEUTICALS CORPORATION Payments to Doctors
See all physicians who received payments from NOVARTIS PHARMACEUTICALS CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology